A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Project: Research

Project Details

StatusFinished
Effective start/end date7/07/22 → 30/04/23

Keywords

  • Phase 1 and 2 study
  • treatment safety
  • treatment efficacy
  • Pharmacokinetics
  • Non-Hodgkin's Lymphoma